Industry-Supported Presentation Theaters

 

Thursday September 30, 2021

VIRTUAL & IN-PERSON
6:45 am - 7:45 am / Marriott 5&6
Title: Discover the Impact of GEMTESA® (vibegron) 75mg tablets, An Effective OAB Treatment: A Fresh Look at OAB Management in Long-Term Care Settings
Supported by: Urovant Sciences

IN-PERSON
6:45 am - 7:45 am / Marriott 3&4
Title: Break the Sequential T2DM Treatment Pattern in adult patients with high A1C on OADs, or uncontrolled on GLP-1 Ras, and get them to goal
Supported by: Sanofi

IN-PERSON
12:30 pm - 1:30 pm / Marriott 3&4
Title: A Long-Term Care Resident With Hallucinations and Delusions Associated with Parkinson's Disease Psychosis
Supported by: Acadia Pharmaceuticals Inc.

Friday October 1, 2021

VIRTUAL & IN-PERSON
7:00 am - 8:00 am / Marriott 5&6
Title: Pseudobulbar Affect (PBA) in a Long-Term Care Setting – Clinical Picture, Diagnosis and Management (MLR-NUE-US-1244-0221)
Supported by: Avanir Pharmaceuticals, Inc.

IN-PERSON
7:00 am - 8:00 am / Marriott 3&4
Title: Managing Insomnia in Patients with Mild to Moderate Alzheimer's Disease
Supported by: Merck

IN-PERSON
12:00 pm - 1:00 pm / Marriott 1&2
Title: Xcopri - A New Anti-Seizure Medicine for the Treatment of Partial Onset Seizures in Adults with Epilepsy
Supported by: SK life science

IN-PERSON
12:00 pm - 1:00 pm / Marriott 3&4
Title: Understanding Alzheimer's Disease: Recognizing and Diagnosing Earlier in the Disease Continuum
Supported by: Biogen

Saturday October 2, 2021

VIRTUAL & IN-PERSON
7:00 am - 8:00 am / Marriott 5&6
Title: A Deeper Dive into the Use of Myrbetriq® (mirabegron) in Patients 65 and Older with OAB Symptoms of Urge Urinary Incontinence, Urgency, and Urinary
Frequency
Supported by: Astellas Pharma US, Inc.

IN-PERSON
7:00 am - 8:00 am / Marriott 3&4
Title: A Treatment Option for the Management of Focal Seizures in Adults, Including Residents of Long-term Care Settings
Supported by: Sunovion Pharmaceuticals Inc.